Document is current
Any future updates will be listed below
-
Authors
Ranganath, Harsha
Jain, Amit L.
Smith, Justin R.
Ryder, Julie
Chaudry, Amina
Miller, Emily
Hare, Felicia
Valasareddy, Poojitha
Seitz, Robert S.
Hout, David R.
Varga, Matthew G.
Schweitzer, Brock L.
Nielsen, Tyler J.
Mullins, Janice
Ross, Douglas T.
Gandara, David R.
Vidal, Gregory A.
- License Information
-
More Information
Article History
Received: 10 December 2021
Accepted: 16 March 2022
First Online: 14 April 2022
Declarations
:
: This study was performed in accordance with the declaration of Helsinki and approved by the University of Tennessee Health Science Center Institutional Review Board (18–05806-xp). Informed consent was obtained from all subjects and or their legal guardians.
: Not applicable.
: RS, DH, MV, BS, DR and TN are employed by Oncocyte Corporation, the commercial entity that markets the 27-gene immuno-oncology algorithm as DetermaIO. DRG reports consultancy work for Oncocyte Corporation. HR, AJ, JS, JR, AC, EM, FH, PV, JM, and GV do not have competing interests to declare.
